Chinese Medicine: The Dangers of Deployment - Webinar Recording/Transcript
Chinese Medicine: The Dangers of Deployment — The Impact on Pharmaceutical Regulatory and Quality Specialists
Do you have concerns about Chinese API’s and chemical intermediates? If so, you’re not the only one.
More than half of all valsartan products on the U.S. market have been recalled due to a probable cancer-causing chemical in the API. The recall shines a spotlight on growing U.S. and global dependence on China for APIs and chemical intermediates.
Talk of proposed tariffs on Chinese pharmaceuticals has raised concerns about the impact on the supply and price of drugs. Tariffs could be disruptive to the market since China is the sole global supplier of many APIs and chemical intermediates. Supply chain modification is burdensome and can affect quality and access to an unfettered supply.
And China wants to become the world’s pharmacy. What do you need to know?
FDAnews has called on Rosemary Gibson — Senior Advisor at the Hastings Center and author of China Rx: Exposing the Risks of America’s Dependence on China for Medicine to discuss the real-world impact of Chinese medicine on public health and the scrutiny it’s undergoing. You’ll learn the following:
- Three lessons from the valsartan case
- Three questions to ask API suppliers to ensure GMP
- The rationale for proposed tariffs on Chinese medical products
- Details of the industry response to tariffs on Chinese-made APIs and chemical intermediates
- The importance of China’s goal to become the world’s pharmacy and the impact on the global supply chain and regulatory oversight
Order today to understand the risks and challenges posed by U.S. dependence on Chinese pharmaceuticals.